Exchange protein directly activated by cyclic adenosine monophosphate 1 (EPAC1)

Exchange protein directly activated by cyclic adenosine monophosphate 1 (EPAC1) is a ubiquitously expressed intracellular signaling protein encoded by the RAPGEF3 gene, functioning as a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPases Rap1 and Rap2 in response to elevated levels of cyclic adenosine monophosphate (cAMP)[1][3][5]. EPAC1 acts as a key downstream effector of cAMP, operating independently of the classic protein kinase A (PKA) pathway[5]. Structurally, EPAC1 contains regulatory domains enabling cAMP binding and catalytic domains that facilitate nucleotide exchange for Rap proteins[1][4]. Upon cAMP binding, EPAC1 undergoes a conformational change and translocates to membrane compartments, where it activates numerous signaling pathways related to cell migration, proliferation, adhesion, apoptosis, gene expression, and organ-specific functions such as cardiac hypertrophy and neurite outgrowth[1][3][4]. EPAC1 has been implicated in several diseases, notably cardiovascular diseases (e.g., heart failure, arrhythmia), neurodegenerative diseases (e.g., Alzheimer’s disease), cancer, diabetes, inflammation, and pain[1][3][5]. Small molecule modulators of EPAC1 (both agonists and antagonists) are being investigated for their therapeutic potential and for dissecting EPAC1’s roles in health and disease, but systemic targeting carries the risk of interfering with important cAMP-dependent physiological processes[1][4].

Other names

EPAC1Rap guanine nucleotide exchange factor 3 (RAPGEF3)cAMP-regulated guanine nucleotide exchange factor 1

Activation (agonism) by direct binding of cAMP analogs to stimulate EPAC1 and facilitate GEF activity for Rap1 and Rap2 Inhibition by small molecule antagonists (e.g., ESI-09, CE3F4) to block signaling and downstream effects